Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Longitudinal associations between exercise and biomarkers in autosomal dominant Alzheimer's disease
Sewell, Kelsey R. , Xiong, Chengjie , Masters, Colin L. , Laske, Christoph , Huey, Edward D. , Hassenstab, Jason , Day, Gregory S. , Fox, Nick C. , Chhatwal, Jasmeer P. , Roh, Jee Hoon , Perrin, Richard J. , Supnet, Charlene , Berman, Sarah , Daniels, Alisha , Noble, James M. , Martins, Ralph N. , Gardener, Samantha L. , Morris, John C. , Erickson, Kirk I. , Sohrabi, Hamid R. , Brown, Belinda M. , Network, The Dominantly Inherited Alzheimer's, Day, Gregory S , Masters, Colin L , Xiong, Chengjie , Fox, Nick C , Hassenstab, Jason , Morris, John C , Roh, Jee Hoon , Supnet-Bell, Charlene , Berman, Sarah , Noble, James M , Doecke, James D. , Xiong, Chengjie , Benzinger, Tammie L.S. , Jucker, Mathias , Lopera, Francisco Javier , Gordon, Brian A. , Llibre‐Guerra, Jorge J. , Schofield, Peter R. , Ibanez, Laura , Lee, Jae‐Hong , Allegri, Ricardo , Rainey‐Smith, Stephanie R. , Peiffer, Jeremiah J. , Bateman, Randall J. , McDade, Eric , Network, The Dominantly Inherited Alzheimer's

Mayo Clinic

Alzheimer's & Dementia | September 26, 2024 | Volume: 20 | Issue: 11 | Pages: 7923-7939

10.1002/alz.14270 | PMID 39324510 Get It

AbstractINTRODUCTIONWe investigated longitudinal associations between self‐reported exercise and Alzheimer's disease (AD)‐related biomarkers in individuals with autosomal dominant AD (ADAD) mutations.METHODSParticipants were 308 ADAD mutation carriers aged 39.7 ± 10.8 years from the Dominantly Inherited Alzheimer's Network. Weekly exercise volume was measured via questionnaire and associations with brain volume (magnetic resonance imaging), cerebrospinal fluid biomarkers, and brain amyloid beta (Aβ) measured by positron emission tomography were investigated.RESULTSGreater volume of weekly exercise at baseline was associated with slower accumulation of brain Aβ at preclinical disease stages β = –0.16 [–0.23 to –0.08], and a slower decline in multiple brain regions including hippocampal volume β = 0.06 [0.03 to 0.08].DISCUSSIONExercise is associated with more favorable profiles of AD‐related biomarkers in individuals with ADAD mutations. Exercise may have therapeutic potential for delaying the onset of AD; however, randomized controlled trials are vital to determine a causal relationship before a clinical recommendation of exercise is implemented.Highlights Greater self‐reported weekly exercise predicts slower declines in brain volume in autosomal dominant Alzheimer's disease (ADAD). Greater self‐reported weekly exercise predicts slower accumulation of brain amyloid beta in ADAD. Associations varied depending on closeness to estimated symptom onset.
Gene-Specific Effects on Brain Volume and Cognition of TMEM106B in Frontotemporal Lobar Degeneration
Vandebergh, Marijne , Ramos, Eliana Marisa , Corriveau‐Lecavalier, Nick , Ramanan, Vijay K. , Kornak, John , Mester, Carly , Kolander, Tyler, Brushaber, Danielle , Staffaroni, Adam M. , Geschwind, Daniel H., Wolf, Amy , Kantarci, Kejal, Petrucelli, Leonard , Broeck, Marleen Van den , Wynants, Sarah , Baker, Matthew , Borrego‐Écija, Sergi , Barmada, Sami J. , Darby, R. Ryan , Domoto‐Reilly, Kimiko , Fields, Julie A. , Ghoshal, Nupur , Graff‐Radford, Neill R. , Grant, Ian , Huey, Edward D. , Kwan, Justin , Litvan, Irene , Masdeu, Joseph C. , Mendez, Mario F. , Onyike, Chiadi U. , Pascual, Belén , Pressman, Peter , Ritter, Aaron, Roberson, Erik D. , Snyder, Allison , Sullivan, Anna Campbell, Wint, Dylan , Heuer, Hilary W. , Forsberg, Leah K. , Boxer, Adam L. , Rosen, Howard J. , Rademakers, Rosa , Kantarci, Kejal , Brushaber, Danielle E, Wolf, Amy A, Gendron, Tania F , Van den Broeck, Marleen, Borrego-Écija, Sergi , Appleby, Brian , Barmada, Sami , Bozoki, Andrea C , Darby, Richard Ryan , Dickerson, Bradford Clark , Domoto-Reilly, Kimiko , Fields, Julie A , Galasko, Douglas , Ghoshal, Nupur , Honig, Lawrence S. , Hsiung, Gink-Yuek , Huey, Edward D , Irwin, David J , Knopman, David S. , Kwan, Justin Y., Léger, Gabriel C, Litvan, Irene , Onyike, Chiadi , Pascual, Belen , Pressman, Peter S, Roberson, Erik , Tartaglia, Maria Carmela , Wint, Dylan , Heuer, Hilary W , Forsberg, Leah K , Boxer, Adam , Rosen, Howard J , Boeve, Brad , Rademakers, Rosa , Kantarci, Kejal , Ramanan, Vijay K , Corriveau-Lecavalier, Nick , Snyder, Allison , Vandebergh, Marijne , Mester, Carly , Geschwind, Daniel H. , Gendron, Tania F. , Appleby, Brian S. , Clark, David, Galasko, Douglas , Hsiung, Ging‐Yuek Robin , Irwin, David J. , Knopman, David S. , Léger, Gabriel C. , Masdeu, Joseph C , Boeve, Bradley F.

Mayo Clinic

Neurology | September 25, 2024 | Volume: 103 | Issue: 8 | Pages: No page available

10.1212/wnl.0000000000209832 | PMID 39321401 Get It

A 59-Year-Old Man with a Rash and Hearing Loss
Amjad, Sarah , Nagaraja, Vivek , Chen, Stella X., Amjad, Sarah A , Nagaraja, Vivek

Mayo Clinic

NEJM Evidence | September 24, 2024 | Volume: 3 | Issue: 10 | Pages: No page available

10.1056/evidmr2400254 | PMID 39315867 Get It

DNA Immunotherapy for Recurrent Respiratory Papillomatosis (RRP): Phase 1/2 study assessing efficacy, safety, and immunogenicity of INO-3107
Morrow, Matthew P. , Gillespie, Elisabeth, Sylvester, Albert J. , Belafsky, Peter C. , Best, Simon R. , Friedman, Aaron D. , Pransky, Seth M. , Tan, Grace , Wisotsky, Sadie, Reuschel, Emma L. , Reed, Katherine , Dallas, Michael, Skolnik, Jeffrey , Morrow, Matthew P. , Klein, Adam M. , Lott, David G. , Mau, Ted , Paniello, Randal C. , Saba, Nabil F. , Tan, Grace S., Marcus, Sarah A. , Weiner, David B , Dallas, Michael J., Skolnik, Jeffrey M.

Mayo Clinic

No container title available | September 18, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4770252/v1 Get It

Abstract Recurrent respiratory papillomatosis (RRP) is a debilitating chronic disease of the airway caused by Human Papillomavirus (HPV). Here we describe the efficacy, safety, and immunogenicity from a Phase 1/2 trial of INO-3107, a DNA immunotherapy designed to elicit T-cell responses against HPV-6 and HPV-11, in adults with RRP (NCT04398433). Thirty-two eligible patients with HPV-6 and/or HPV-11 RRP, who required ≥2 surgical interventions in the year preceding dosing, were administered 4 doses of INO-3107 by intramuscular (IM) injection followed by electroporation (EP). The primary endpoint was safety and tolerability. Efficacy and immunology endpoints included the frequency of surgical interventions in the year following the first dose of INO-3107 and assessment of immune responses. The majority (26/32; 81%) of patients experienced a reduction in the number of surgeries in the year following initiation of treatment with INO-3107, when compared with the year prior. Peripheral blood assessments revealed HPV-6 and HPV-11 antigen-specific T-cell induction, inclusive of cytolytic CD8+ T-cells. RNA sequencing identified the presence of an inflammatory response in patient papillomas after treatment with INO-3107, inclusive of cytolytic CD8+ T-cell signatures. T-cell receptor sequencing revealed emergent T-cell clones in the blood and assessment of airway tissue confirmed trafficking of these clones to papillomas, which was associated with clinical benefit. Treatment was well tolerated, with 13/32 (41%) patients reporting a treatment-related adverse event (AE), all of which were low-grade. INO-3107 provides clinical benefit to adults with HPV-6 and/or HPV-11 associated RRP, is well tolerated, and generates an antigen-specific immune response against HPV. Importantly, treatment-induced peripheral T-cell responses traffick to airway tissue and are associated with clinical response, consistent with the proposed mechanism of action.
Apixaban anti‐Xa levels in clinical practice: A case report
Clark, Sarah L. , Alcalá-Zermeño, Juan Luis

Mayo Clinic

British Journal of Clinical Pharmacology | September 17, 2024 | Volume: 90 | Issue: 11 | Pages: 2935-2938

10.1111/bcp.16247 | PMID 39285695 Get It

AbstractApixaban is a widely used direct oral anticoagulant that is recommended over warfarin therapy for many clinical indications. In patients with atrial fibrillation, dose reductions are recommended for patients with advanced age (≥80 years), low weight (≤60 kg) or elevated serum creatinine (≥1.5 mg/dL), but there is no routine laboratory monitoring necessary for long term‐use. Furthermore, apixaban dose reductions due to renal dysfunction are not recommended when treating acute venous thromboembolism. Apixaban‐calibrated anti‐Xa assays are readily available at some medical centres, and they may be of clinical utility in certain circumstances such as in patients with renal insufficiency, medication adherence assessment, periprocedural planning, extremes in body weight and advanced age. Here, we describe the case of an elderly patient with chronic kidney disease taking apixaban for acute pulmonary embolism. The patient had an unanticipated prolonged apixaban half‐life, with detectable apixaban‐calibrated anti‐Xa levels for >10 days after the last administered dose, which delayed a necessary surgical intervention by >1 week. This case is an example of appropriately using apixaban‐calibrated anti‐Xa levels to guide therapeutic decision making in perioperative planning.
Abstract B012: Randomized phase II trial of two different nutritional approaches for patients receiving treatment for their advanced pancreatic cancer: initial results of safety and feasibility of the medically supervised ketogenic diet
Jameson, Gayle , Borazanci, Erkut , Hanna, Diana L. , Pelster, Meredith S. , Frank, Richard C. , Alistar, Angela , Wiedmeier, Julia E. , Algaze, Sandra , Fell, Brandon, Hallberg, Sarah J. , Roe, Denise J. , Wertheim, Betsy C. , Cridebring, Derek , Rabinowitz, Joshua D. , Gately, Stephen, Hoff, Daniel D. Von , Rasco, Drew , Wiedmeier-Nutor, Julia E , Borazanci, Erkut , Roberts, Caroline G. P.

Mayo Clinic

Cancer Research | September 15, 2024 | Volume: 84 | Issue: 17_Supplement_2 | Pages: B012-B012

10.1158/1538-7445.pancreatic24-b012 Get It

Abstract Background: Pancreatic ductal adenocarcinoma (PDAC) is characterized by stromal fibrosis, hypoxia, and nutritional deprivation. Nutritional metabolic interventions may fundamentally change the tumor microenvironment and improve outcomes. A ketogenic diet (KD) (lower carbohydrate, moderate protein, higher fat) can significantly reduce glucose and insulin and stimulate ketogenesis. Triplet chemotherapy with gemcitabine/cisplatin/nab-paclitaxel has been associated with a median OS 16.4 months, PFS 10.1 months in patients with metastatic PDAC in the first-line setting. Recently, KD plus triplet chemotherapy was shown to inhibit murine pancreatic KPC tumor growth and prolong animal survival over chemotherapy alone (Yang et al, Med, 2022). Tumor growth inhibition was associated with glucose depletion, altered TCA substrate use and NADH elevation. Methods: In this Phase II trial, patients with treatment-naive metastatic PDAC were randomized to triplet chemotherapy with a medically supervised ketogenic diet (MSKD) or continuing their usual diet (non-MSKD). The MSKD is supported by Virta Health, who offers tracking of daily ketone (beta-hydroxybutyrate, BHB) and glucose levels, a web-based application, education, and communication with a remote care team to ensure sustained nutritional ketosis (BHB 0.5–3.0mM). Patients with BMI < 18, type 1 DM or history of DKA were excluded. Primary endpoint was PFS. Secondary endpoints: DCR (PR+CR+SD ≥ 9 weeks), change in CA 19-9 (CA125, CEA if not CA 19-9 expressers), average fasting insulin levels, HbA1c, body weight, gut microbiome, serum metabolites, QOL (QLQ- C30). Results: A total of 36 patients with untreated metastatic PDAC were enrolled. Among 32 evaluable patients (median age 65.9 years; 53% male), 16 were randomized to each arm. Both groups had similar baseline weight, HgbA1c, insulin and BHB levels (all p>0.05). Nine patients had type 2 DM; 6 required insulin. In the MSKD group, 15/16 achieved nutritional ketosis at any point during the study, with mean BHB of 0.57 mM (95% CI 0.40–0.73) and median proportion of days in ketosis of 39.4% (range 0-95.8%) by daily ketone tracking. Lab data showed significantly higher mean ± SD maximum change in BHB in the MSKD (0.5 ± 0.9 mmol/L) versus non-MSKD (–0.2 ± 0.3 mol/L) group (p = 0.018). There were no significant differences between groups in maximum change in weight, HbA1C, or insulin (all p > 0.05). The most common MSKD-related adverse events were Gr 1-2 fatigue (n=4), constipation (n=3), weight loss (n=3), and none stopped MSKD due to adverse events.Conclusion: A medically supervised ketogenic diet is feasible in patients with metastatic PDAC receiving triplet chemotherapy, with median proportion of days in ketosis of 39.4% and an acceptable safety profile. The MSKD is associated with comparable changes in insulin and HgbA1c levels compared to the non-MSKD diet, and sustained ketosis does not result in significantly greater weight loss. MSKD warrants further prospective exploration and analyses of the primary endpoint and correlative studies are ongoing. Citation Format: Gayle S Jameson, Erkut Borazanci, Diana L Hanna, Caroline GP Roberts, Meredith S Pelster, Richard C Frank, Angela T Alistar, Julia E Wiedmeier-Nutor, Sandra D Algaze, Brandon Fell, Sarah J Hallberg, Denise J Roe, Betsy C Wertheim, Derek Cridebring, Joshua D Rabinowitz, Stephen Gately, Daniel D Von Hoff, Drew W Rasco. Randomized phase II trial of two different nutritional approaches for patients receiving treatment for their advanced pancreatic cancer: initial results of safety and feasibility of the medically supervised ketogenic diet [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer Research; 2024 Sep 15-18; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2024;84(17 Suppl_2):Abstract nr B012.
A pleiotropic recurrent dominant ITPR3 variant causes a complex multisystemic disease
Molitor, Anne , Lederle, Alexandre , Radosavljevic, Mirjana , Sapuru, Vinay , Thomas, Megan E. Zavorka, Yang, Jianying , Shirin, Mahsa , Collin-Bund, Virginie , Jeřábková, Kateřina , Miao, Zhichao , Bernard, Alice , Grenot, Pierre , Lewis, Elyssa G., Person, Richard, Esperón-Moldes, Uxía-Saraiva, Kaare, Milja, Nokelainen, Pekka, Batzir, Nurit Assia , Hoffer, Gal Zaks, Stemmelen, Tristan , Naegely, Lydie , Hanauer, Antoine , Bibi‐Triki, Sabrina , Grün, Sarah, Jung, Sophie , Busnelli, Ignacio, Tripolszki, Kornélia , Ordoñez, Natalia, Song, Eunkyung , Zajo, Kristin , Partida‐Sánchez, Santiago , Robledo‐Avila, Frank , Kumánovics, Attila , Pichot, Angélique , Toker, Ori , Mejía, César , Parvaneh, Nima , Knapp, Esther , Hersh, Joseph H., Kenney, Heather , Bajwa, Rajinder , Thomas, Caroline , Ehl, Stephan , Isidor, Bertrand , Abraham, Roshini S. , Hite, Richard K. , Bertoli‐Avella, Aida M. , Bahram, Seiamak , Zavorka Thomas, Megan E , Jerabkova-Roda, Katerina , Rolli, Véronique , Grenot, Pierre , Castro, Carla Noemi , Rosenzwajg, Michelle , Person, Richard , Batzir, Nurit Assia , Hoffer, Gal Zaks , Paul, Nicodème , Stemmelen, Tristan , Naegely, Lydie , Hanauer, Antoine , Bibi-Triki, Sabrina , Jung, Sophie , Bauer, Peter , Zajo, Kristin , Partida-Sanchez, Santiago , Robledo-Avila, Frank , Kumanovics, Attila , Louzoun, Yoram , Hirschler, Aurélie , Pichot, Angélique , Toker, Ori , Mejía, Cesar Andrés Muñoz , Parvaneh, Nima , Knapp, Esther , Delmonte, Ottavia M , Notarangelo, Luigi D , Goetz, Jacky G , Kahwash, Samir B , Carapito, Christine , Bajwa, Rajinder P S , Thomas, Caroline , Ehl, Stephan , Isidor, Bertrand , Carapito, Raphael , Abraham, Roshini S , Hite, Richard K , Bahram, Seiamak , Esperón-Moldes, Uxia , Al‐Ali, Ruslan , Kenney, Heather , Kahwash, Samir B. , Marcus, Nufar

Mayo Clinic

Science Advances | September 13, 2024 | Volume: 10 | Issue: 37 | Pages: No page available

10.1126/sciadv.ado5545 | PMID 39270020 Get It

Inositol 1,4,5-trisphosphate (IP3) receptor type 1 ( ITPR1 ), 2 ( ITPR2 ), and 3 ( ITPR3 ) encode the IP3 receptor (IP3R), a key player in intracellular calcium release. In four unrelated patients, we report that an identical ITPR3 de novo variant—NM_002224.3:c.7570C>T, p.Arg2524Cys—causes, through a dominant-negative effect, a complex multisystemic disorder with immunodeficiency. This leads to defective calcium homeostasis, mitochondrial malfunction, CD4 + lymphopenia, a quasi-absence of naïve CD4 + and CD8 + cells, an increase in memory cells, and a distinct TCR repertoire. The calcium defect was recapitulated in Jurkat knock-in. Site-directed mutagenesis displayed the exquisite sensitivity of Arg 2524 to any amino acid change. Despite the fact that all patients had severe immunodeficiency, they also displayed variable multisystemic involvements, including ectodermal dysplasia, Charcot-Marie-Tooth disease, short stature, and bone marrow failure. In conclusion, unlike previously reported ITPR1-3 deficiencies leading to narrow, mainly neurological phenotypes, a recurrent dominant ITPR3 variant leads to a multisystemic disease, defining a unique role for IP3R3 in the tetrameric IP3R complex.
Central Venous Oxygen Saturation for Estimating Mixed Venous Oxygen Saturation and Cardiac Index in the ICU: A Systematic Review and Meta-Analysis
Motazedian, Pouya, Beauregard, Nickolas , Létourneau, Isabelle J., Olaye, Ida, Syed, Sarah , Lam, Eric, Santo, Pietro Di , Mathew, Rebecca , Hibbert, Benjamin , Bugeja, Ann , Hibbert, Benjamin , Motazedian, Pouya , Olaye, Ida-Ehosa, Clark, Edward G. , Sood, Manish M. , Lalu, Manoj Mathew

Mayo Clinic

Critical Care Medicine | September 11, 2024 | Volume: 52 | Issue: 11 | Pages: e568-e577

10.1097/ccm.0000000000006398 | PMID 39258966 Get It

OBJECTIVES: The objectives of our systematic review and meta-analyses were to determine the diagnostic accuracy of central venous oxygen saturation (Scvo 2) in estimating mixed venous oxygen saturation (Svo 2) and cardiac index in critically ill patients. DATA SOURCES: A systematic search using MEDLINE, Cochrane Central Register of Controlled Trials, and Embase was completed on May 6, 2024. STUDY SELECTION: Studies of patients in the ICU for whom Scvo 2 and at least one reference standard test was performed (thermodilution and/or Svo 2) were included. DATA EXTRACTION: Individual patient data were used to calculate the pooled intraclass correlation coefficient (ICC) for Svo 2 and Spearman correlation for cardiac index. The Quality Assessment of Diagnostic Accuracy Studies-2 and Grading Recommendations Assessment, Development, and Evaluation tools were used for the risk of bias and certainty of evidence assessments. DATA SYNTHESIS: Of 3427 studies, a total of 18 studies with 1971 patients were identified. We meta-analyzed 16 studies (1335 patients) that used Svo 2 as a reference and three studies (166 patients) that used thermodilution as reference. The ICC for reference Svo 2 was 0.83 (95% CI, 0.75–0.89) with a mean difference of 2.98% toward Scvo 2. The Spearman rank correlation for reference cardiac index is 0.47 (95% CI, 0.46–0.48; p < 0.0001). CONCLUSIONS: There is moderate reliability for Scvo 2 in predicting Svo 2 in critical care patients with variability based on sampling site and presence of sepsis. There is limited evidence on the independent use of Scvo 2 in predicting cardiac index.
Development of a Breast Cancer Risk Prediction Model Integrating Monogenic, Polygenic, and Epidemiologic Risk
Kalia, Sarah S. , Boddicker, Nicholas , Yadav, Siddhartha , Huang, Hongyan , Na, Jie , Ambrosone, Christine B. , Yao, Song , Haiman, Christopher A. , Chen, Fei , John, Esther M. , Kurian, Allison W. , Guo, Boya , Lindström, Sara , Auer, Paul L. , Taylor, Jack A. , Hodge, James M. , Lori, Adriana , Bodelón, Clara , Vachon, Celine M. , Goldgar, David E. , Nathanson, Katherine L. , Weitzel, Jeffrey N. , Boddicker, Nicholas J , Hu, Chunling , Ambrosone, Christine B , Yao, Song , Haiman, Christopher A , Chen, Fei , John, Esther M , Kurian, Allison W , Guo, Boya , Lindstrom, Sara , Auer, Paul , Lacey, James V. , Neuhausen, Susan L. , Martı́nez, Marı́a Elena , Sandler, Dale P , O'Brien, Katie M , Taylor, Jack A , Teras, Lauren R , Hodge, James M , Lori, Adriana , Bodelon, Clara , Trentham-Dietz, Amy , Burnside, Elizabeth S , Vachon, Celine M. , Winham, Stacey J , Goldgar, David E , Domchek, Susan M , Nathanson, Katherine L , Weitzel, Jeffrey N , Couch, Fergus J. , Kraft, Peter , Yadav, Siddhartha , Na, Jie , Hu, Chunling , Sandler, Dale P. , O’Brien, Katie M. , Teras, Lauren R. , Trentham‐Dietz, Amy , Burnside, Elizabeth S. , Winham, Stacey J. , Domchek, Susan M. , Couch, Fergus J. , Kraft, Peter

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | September 11, 2024 | Volume: 33 | Issue: 11 | Pages: 1490-1499

10.1158/1055-9965.epi-24-0594 | PMID 39259185 Get It

Abstract Background: Breast cancer has been associated with monogenic, polygenic, and epidemiologic (clinical, reproductive, and lifestyle) risk factors, but studies evaluating the combined effects of these factors have been limited. Methods: We extended previous work in breast cancer risk modeling, incorporating pathogenic variants (PV) in six breast cancer predisposition genes and a 105-SNP polygenic risk score (PRS), to include an epidemiologic risk score (ERS) in a sample of non-Hispanic White women drawn from prospective cohorts and population-based case–control studies, with 23,518 cases and 22,832 controls, from the Cancer Risk Estimates Related to Susceptibility (CARRIERS) Consortium. Results: The model predicts 4.4-fold higher risk of breast cancer for postmenopausal women with no predisposition PV and median PRS, but with the highest versus lowest ERS. Overall, women with CHEK2 PVs had &gt;20% lifetime risk of breast cancer. However, 15.6% of women with CHEK2 PVs and a family history of breast cancer, and 45.1% of women with CHEK2 PVs but without a family history of breast cancer, had low (&lt;20%) predicted lifetime risk and thus were below the threshold for MRI screening. CHEK2 PV carriers at the 10th percentile of the joint distribution of ERS and PRS, without a family history of breast cancer, had a predicted lifetime risk similar to the general population. Conclusions: These results illustrate that an ERS, alone and combined with the PRS, can contribute to clinically relevant risk stratification. Impact: Integrating monogenic, polygenic, and epidemiologic risk factors in breast cancer risk prediction models may inform personalized screening and prevention efforts.